A Short Report

Radiotherapy Treats a Greater Volume than Surgery Using an Axillary Sentinel Node Model

Timothy Wong¹, April Wong², Raef Awad³, Lauren Haydu⁴, Nicole Dougheney⁵, Gerald Fogarty⁶*

¹School of Medicine
University of Notre Dame Sydney, Australia
E-mail: twong283@gmail.com

²Breast & Oncology Centre
The Poche Centre
North Sydney, Australia
E-mail: draprilwongsurgery@gmail.com

³Royal Hobart Hospital
Tasmania, Australia
E-mail: raef.awad@dhhs.tas.gov.au

⁴MD Anderson Hospital
University of Texas
Houston, USA
E-mail: LEHaydu@mdanderson.org

⁵Genesis Cancer Care Radiation Oncology Department
The Mater Hospital
North Sydney, Australia
E-mail: Nicole.Dougheney@cancer.com.au

⁶Genesis Cancer Care Radiation Oncology Department
Suite 708 St Vincents Clinic
438 Victoria St
Darlinghurst NSW 2010, Australia
E-mail: Gerald.Fogarty@cancer.com.au

*Corresponding author

Received: July 26, 2016
Accepted: November 10, 2016
Published: December 31, 2016

Abstract: Radiotherapy and surgery are local treatments and can be compared in randomized trials. Recent examples have compared axillary radiotherapy to completion lymphadectomy surgery for sentinel lymph node positive breast cancer and have shown radiotherapy was non-inferior in terms of regional control, but was also significantly less morbid. A superficial reading of these studies may miss an important consideration, the volume of the axilla actually being treated by the different modalities. We conducted this study to compare the difference in planned axillary treatment volumes undergoing axillary lymph node dissection as compared to axillary radiotherapy.

Keywords: Breast neoplasm, General surgery, Radiotherapy, Sentinel lymph node biopsy, Axilla, Local control, Regional control.
Introduction
Radiotherapy (RT) and surgery (Sx) are local treatments and can be compared in randomized trials. With drastic improvements in RT such as the emergence of Volumetric Modulated Arc Therapy (VMAT), RT offers a safe alternative to Sx due to its conformity and reduced dosage [5]. Recent studies have compared axillary RT to completion lymphadenectomy Sx for sentinel lymph node positive (SLN+) breast cancer. Sentinel lymph node biopsy (SLNB) allows pathological staging of the clinically negative axilla. The Z0011 randomized controlled trial (RCT) in 891 patients with T1-T2 breast cancer with 1 to 2 sentinel lymph node positive (SLN+) compared completion axillary lymphadenectomy (ALND) with observation [3]. All patients underwent lumpectomy and tangential whole-breast RT. The trial showed that observation was not inferior to further ALND. Discussion afterwards suggested that the RT tangents may have incidentally sterilized any remaining regional disease.

Should the SLN+ axilla be specifically treated? The AMAROS trial was designed to answer this question. This RCT compared axillary RT to ALND in 1425 T1-2 primary breast cancer patients with SLN+ axillas. With a median follow-up of 6.1 years, the trial showed that RT was non-inferior in terms of regional control, but was significantly less morbid [1].

A superficial reading of these studies may miss an important consideration, the volume of the axilla actually being treated by the different modalities. We conducted this study in order to see whether there was a difference in treatment volumes.

Materials and methods
Ten consecutive post-operative patients with T1-2 breast cancer who required RT planning were simulated on a GE Light Speed CT Scanner for RT in the usual treatment position, with arms above the head on a breast board (CIVCO; Iowa, USA). Acquired scans were loaded into Eclipse planning system version 8.6 (Varian; Palo Alto, USA) for volume contouring. A breast surgeon (BS) (AW), and a radiation oncologist (RO) (RSA) with a subspecialty in breast RT, then contoured the Sx and RT volumes, without knowledge of each other’s contours, using the contouring tools of free brush, pencil and the paintbrush. The contoured volumes for Sx and RT are shown in Fig. 1.

Fig. 1 Axial planning computer image demonstrating the contouring of the axilla by a radiation oncologist (green) and a breast surgeon (red). Note the difference in the treatment volume.
BS contoured according to her interpretation of the volumes detailed in McMinn (2003) [4].
The RO contoured according to Radiation Therapy Oncology group (RTOG) breast cancer
atlas for radiation therapy planning [6] and axillary volumes published for other cancers [2].
The RO and BS axillary volumes were calculated in cubic centimetres (cc) using the volume
tools of the software, and compared using the Wilcoxon Signed Rank Test. A p-value less
than 0.05 was considered statistically significant.

Results and discussion
The planned median surgical volume was 44.5 cc (range 24-94) and median radiotherapy
volume was 78.5 cc (range 47-167) (Table 1). The planned RO treatment volumes were
significantly greater than the BS volumes (z = -2.8, p = 0.005).

<table>
<thead>
<tr>
<th>Patient number</th>
<th>Surgical volume, (cc)</th>
<th>Radiotherapy volume, (cc)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>49</td>
<td>78</td>
</tr>
<tr>
<td>2</td>
<td>29.7</td>
<td>67.3</td>
</tr>
<tr>
<td>3</td>
<td>40</td>
<td>79</td>
</tr>
<tr>
<td>4</td>
<td>39.7</td>
<td>74.3</td>
</tr>
<tr>
<td>5</td>
<td>24</td>
<td>47</td>
</tr>
<tr>
<td>6</td>
<td>56</td>
<td>99</td>
</tr>
<tr>
<td>7</td>
<td>75</td>
<td>94</td>
</tr>
<tr>
<td>8</td>
<td>72</td>
<td>167</td>
</tr>
<tr>
<td>9</td>
<td>24</td>
<td>51</td>
</tr>
<tr>
<td>10</td>
<td>94</td>
<td>143</td>
</tr>
<tr>
<td><strong>Median volume</strong></td>
<td><strong>44.5</strong></td>
<td><strong>78.5</strong></td>
</tr>
</tbody>
</table>

Our study showed a significant difference in the planned treatment volumes between RT and
Sx in ten consecutive post-operative patients with T1-2 breast cancer. The BS would treat a
median volume of 44.5 cc, the RO a median volume of 78.5 cc (p = 0.005).

RT treats a significantly greater volume, yet the results of Donker et al. [1] shows that, despite
this bigger volume, the side effects, especially lymphedema, are less with RT alone than with
Sx alone. The studies showed that RT was non–inferior to Sx with oncological outcomes.
Given the volume treated was almost doubled, the scene is set to study whether RT is
superior.

Conclusion
This short report confirmed that there is a significant difference in the axillary volumes
planned to be treated by a BS as compared to a RO in ten consecutive post-operative patients
with T1-2 breast cancer. The median Sx volume was defined at 44.5 cc (range 24-94).
The median RT volume was 78.5 cc (range 47-167) (p = 0.005). The RT volume is more than
1.75 times than the Sx volume. This fact may need to be taken into account in any future
studies.
Acknowledgements
The authors would also like to acknowledge assistance from the staff of the Radiation Oncology Department at the Mater Hospital, Sydney, for assisting in data collection.

Competing interests
There are no significant competing personal, professional or financial interests.

References

Mr. Timothy Wong, M.Sc. Student
E-mail: twong283@gmail.com

Mr. Wong is previously graduated from Queensland University of Technology in Bachelor of Radiological Sciences majoring in Medical Imaging Technology. He is currently studying at School of Medicine, University of Notre Dame Sydney.
Dr. April Wong
E-mail: draprilwongsurgery@gmail.com

Dr. April Wong is a Fellow of the Royal Australasian College of Surgeons. She trained at Royal Prince Alfred Hospital and Prince of Wales Hospital network. She has a Master of Surgery from the University of Sydney. She underwent two years of subspecialty training in Breast surgery including oncoplastic techniques, working in Australia, New Zealand and UK, through the BreastSurgANZ post fellowship program, with further education and training programs by oncology institutes Scuola di Oncologia Chirurgica Ricostruttiva, Italy, and Ecole Europeenne de Chirurgie, France. Dr. Wong also completed a fellowship at Melanoma Institute, Australia.

Dr. Raef Awad
E-mail: raef.awad@dhhs.tas.gov.au

Dr. Raef Awad is a Senior Radiation Oncologist in Hobart. Primary clinical interests include CNS, gastro-intestinal, gynecological and prostate malignancies. Major research efforts include advanced radiation therapy treatment planning including intensity modulated radiation therapy and stereotactic radiosurgery. He has trained and worked in Egypt, Saudi and the US.

Lauren Haydu, Ph.D. Student
E-mail: LEHaydu@mdanderson.org

Lauren Haydu is Data scientist, Clinical Research Statistician and Academic Melanoma Researcher with chemical engineering training, molecular biology experience and master of international public health. Seven years of management experience on-going. Concurrently working part-time towards a Ph.D. on the staging and prognosis of melanoma patients, and the analysis of factors that influence decisions about clinical management.
Nicole Dougheney
E-mail: Nicole.Dougheney@cancer.com.au

Nicole Dougheney is a Senior Radiation Therapist at Genesis Cancer Care North Sydney. She specializes in volumetric modulated arc therapy.

Prof. Gerald Fogarty
E-mail: Gerald.Fogarty@cancer.com.au

Professor Gerald Fogarty is the Director of the Mater Sydney Radiotherapy Centre. He is also on staff at the Melanoma Institute of Australia, the Skin and Cancer Foundation, St. Vincent’s and Macquarie University Hospitals in Sydney. He has spearheaded the use of intensity modulated radiotherapy, a modern radiotherapy technique, in these departments.